Understanding the mechanisms of resistance to BRAF inhibitors in colorectal cancer

Mutations in proto-oncogene BRAF occur in about 10-15% of CRC patients and BRAFV600E is the most common. Most patients with BRAFV600E metastatic CRC show reduced survival compared to patients with wild-type BRAF. For patients who undergo BRAF-targeted therapy, resistance develops 4-6 months after treatment initiation and results in more aggressive disease. We established PT130 cells resistant to PLX8394, a novel BRAF inhibotor, and tested them in vitro and in vivo. Overall design: To invesigate the differences in PT130 Parental and PT130 PLX 8394 Resistant cells both in vitro and in vivo